Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatinresistant cell line to oxaliplatin by inhibiting excision repair crosscomplementing group 1 protein expression.
Oncol Rep
; 42(5): 1725-1734, 2019 Nov.
Article
en En
| MEDLINE
| ID: mdl-31436301
Oxaliplatin (Oxa)based chemotherapy is widely used as the firstline treatment for colorectal cancer (CRC). However, Oxaresistance is common for many postoperative CRC patients. To explore drug resistance in CRC, an Oxaresistant cell line, HCT116/Oxa, was established from parental HCT116 cells. These Oxaresistant cells exhibited characteristics of epithelialmesenchymal transition (EMT) and a higher migratory capacity than parental cells. Protein profiles of HCT116/Oxa and HCT116 cells were compared using a tandem mass tagbased quantitative proteomics technique. The protein dehydrogenase/reductase SDR family member 2 (DHRS2) was revealed to be highly expressed in HCT116/Oxa cells. Silencing of DHRS2 in HCT116/Oxa cells effectively restored Oxasensitivity by suppressing the expression of excision repair crosscomplementing group 1 protein via a p53dependent pathway, and reversed the EMT phenotype. Overall, the suppression of DHRS2 expression may be a promising strategy for the prevention of Oxaresistance in CRC.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Resistencia a Antineoplásicos
/
Proteínas de Unión al ADN
/
Endonucleasas
/
Carbonil Reductasa (NADPH)
Límite:
Humans
Idioma:
En
Revista:
Oncol Rep
Asunto de la revista:
NEOPLASIAS
Año:
2019
Tipo del documento:
Article
Pais de publicación:
Grecia